Morgan Stanley Call 250 AMG 21.06.../ DE000MB795U7 /
03/05/2024 18:15:49 | Chg.- | Bid22:00:32 | Ask22:00:32 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
23.12EUR | - | - Bid Size: - |
- Ask Size: - |
AMGEN INC. DL-... | 250.00 - | 21/06/2024 | Call |
GlobeNewswire
15:00
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
13:30
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire
09:00
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
13/05
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
08/05
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
02/05
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Canc...
GlobeNewswire
01/05
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
01/05
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
30/04
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...